Please regularly visit the following Web sites and directly search for funding opportunities and deadlines in your research field.
Grants.gov: A central storehouse that lists all current funding opportunities from agencies of the United States government, including NIH, NSF, DOD, EPA, DOE, CDC, FDA, AHRQ, CMMS, and so on.
NIH Grants & Funding: A searchable database maintained by the NIH Office of Extramural Research on currently available biomedical research funding and training opportunities related to human health and diseases.
NSF Funding: The Foundation supports basic research and education in most fields, including biological, chemical, environmental, social, behavioral and economical sciences, collaborative research between universities and industry, and graduate and postdoctoral fellowships.
USDA NIFA Grants: Supports research and fellowships on nutrition and health, education, environment, biotechnology and genomics, economics and community development.
AHRQ Funding & Grants: Supports research to improve the quality, safety, efficiency, and effectiveness of healthcare for all Americans.
PCORI Funding: Funds research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed healthcare decisions.
DOD Grants: Department of Defense Appropriations Act provides funding for many peer reviewed biomedical research programs managed by the Department of Defense (DOD) Office of Congressionally Directed Medical Research Programs (CDMRP). Such programs are usually announced between May and July for the following fiscal year.
DARPA (Defense Advanced Research Projects Agency): Funds research that investigates approaches advancing science, techonology, biology, engineering and computer sciences.
Proposal Central (Alzheimer’s Association, American Association for Cancer Research, Neilsen Foundation, Cystic Fibrosis Foundation, Epilepsy Foundation, Juvenile Diabetes Research Foundation, Lupus Foundation of America, Melanoma Research Foundation, Muscular Dystrophy Association, The Leukemia & Lymphoma Society, and others)
American Liver Foundation
American Asthma Foundation
American Brain Tumor Association
American Diabetes Association
American Heart Association
American Institute for Cancer Research
American Lung Association
American Respiratory Care Foundation
Arthritis National Research Foundation
Cancer Research Institute
Human Frontier Science Program
National Foundation for Infectious Diseases
National Pharmaceutical Council
Prostate Cancer Foundation
Susan G. Komen for the Cure
International Rett Syndrome Foundation
Standard due dates for competing NIH applications
NIH Discovery of In Vivo Chemical Probes (R01) support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes. Applications are accepted according to the standard AIDS dates until expiration of the notice. Expiration Date: September 8, 2017
NIH Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UH2/UH3) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Multiple deadline dates listed through February 2017
NIH Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) supports research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Multiple deadline dates listed through September 2016
Last updated on: 6/7/2016 1:20 PM
Kirsten F. Block, Ph.D.Associate Director of Research and Graduate Programs703-739-2330 ext. 1042
Joan M. Lakoski, Ph.D.Vice President of Research and Graduate EducationChief Science Officer703-739-2330 ext. 1040